Ebola Outbreak Surges in DRC as WHO Weighs Experimental Vaccines

By VirentaNews Staff — May 21, 2026

More than 500 suspected Ebola cases and at least 130 deaths have been reported in the Democratic Republic of the Congo, triggering alarm among global health authorities and prompting the World Health Organization (WHO) to consider the emergency use of experimental vaccines. The outbreak, caused by the Bundibugyo strain—an uncommon and less-studied variant of the Ebola virus—has rapidly spread across Ituri Province in eastern DRC, a region already destabilized by armed conflict and weak healthcare infrastructure. WHO Director-General Dr. Tedros Adhanom Ghebreyesus described the situation as deeply concerning, emphasizing that the speed and geographic dispersion of the outbreak could overwhelm local response capacity without immediate international support.

Rising Infection Rates and Strain on Health Systems

As of mid-May 2026, the DRC’s Ministry of Health has recorded 512 suspected Ebola cases, including 130 confirmed or probable deaths, with a case fatality rate hovering near 25%—lower than historical outbreaks but still alarming given the region’s vulnerabilities. The Bundibugyo strain, first identified in Uganda in 2007, is less transmissible than the Zaire variant but remains deadly and challenging to diagnose due to overlapping symptoms with malaria and typhoid. According to WHO field reports, over 60% of cases are concentrated in remote, conflict-affected areas of Ituri, where only 30% of health facilities remain operational. WHO Situation Report No. 14 confirms that contact tracing is severely hampered by population displacement and community mistrust, with nearly 1,800 high-risk contacts currently unaccounted for. Laboratory confirmation delays have further slowed containment, as samples require transport to Kinshasa or Uganda for PCR testing.

Key Actors Mobilizing Amid Political and Logistical Hurdles

The response is being led by the DRC’s National Institute for Biomedical Research (INRB), supported by WHO, Médecins Sans Frontières (MSF), and the Africa Centres for Disease Control and Prevention (Africa CDC). However, coordination remains fragmented due to ongoing clashes between armed groups and Congolese forces in Ituri, which have disrupted supply routes and endangered health workers. In late April, an MSF treatment center in Bunia was temporarily evacuated after militia activity surged nearby. Meanwhile, the U.S. Centers for Disease Control and Prevention (CDC) has deployed a rapid response team to assess the feasibility of deploying investigational vaccines, including the mRNA-based Ebola candidate developed by Moderna in partnership with the NIH. Gavi, the Vaccine Alliance, has signaled readiness to fund emergency procurement if WHO grants an Emergency Use Listing (EUL), but regulatory approval remains pending.

Trade-Offs: Speed Versus Safety in Vaccine Deployment

The prospect of using unlicensed vaccines presents ethical and logistical dilemmas. The rVSV-ZEBOV vaccine, proven effective against the Zaire strain during the 2018–2020 Kivu outbreak, offers no protection against Bundibugyo, leaving no approved vaccine currently available. Experimental candidates, such as Moderna’s mRNA-1944 and a multivalent adenovirus vector vaccine from Johnson & Johnson, are in Phase 1 or 2 trials and lack efficacy data in humans. Deploying them under compassionate use protocols could accelerate containment but risks eroding public trust if adverse events occur. Conversely, delaying intervention may allow the virus to spread beyond Ituri into densely populated urban centers like Kisangani or even across borders into South Sudan and Uganda. Modeling by the London School of Hygiene & Tropical Medicine suggests that without mass vaccination, the outbreak could exceed 2,000 cases within six months.

Why Now? A Confluence of Vulnerabilities and Viral Timing

This outbreak emerges at a precarious moment for global health governance. The DRC is already managing concurrent epidemics of cholera, measles, and mpox, stretching its limited public health resources. The return of Ebola in a new strain revives traumatic memories of past crises, including the 2018–2020 outbreak that killed over 2,200 people—the second-deadliest in history. Increased human encroachment into forested areas, climate-driven shifts in animal reservoirs, and persistent underinvestment in African health infrastructure have created fertile ground for zoonotic spillover. Moreover, the WHO’s recent reforms to emergency financing and decision-making—initiated after criticism during the COVID-19 pandemic—mean that recommendations for experimental interventions may be faster but are under intense scrutiny for transparency and equity.

Where We Go From Here

In the next six to twelve months, three scenarios could unfold. First, if WHO approves emergency use of a candidate vaccine and security conditions improve, a ring vaccination strategy could contain the outbreak by late 2026, mirroring past successes. Second, if transmission accelerates and crosses international borders, the outbreak could be declared a Public Health Emergency of International Concern (PHEIC), triggering coordinated global action. Third, persistent insecurity and vaccine hesitancy could lead to endemic circulation in eastern DRC, turning Ebola into a chronic health threat rather than an acute emergency. Each path hinges on funding, community engagement, and the speed of regulatory decisions.

Bottom line — the DRC’s Ebola outbreak demands urgent, science-driven intervention, but the decision to deploy experimental vaccines must balance innovation with ethical rigor and local trust to avoid worsening the crisis.

Source: The Guardian